Norman E. Sharpless, MD, Sworn in as Director of the National Cancer Institute
Norman E. “Ned” Sharpless, MD, took the oath of office late Tuesday, October 17, 2017, to become the 15th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). He succeeds Harold E. Varmus, MD, who stepped down as Director in March 2015. Douglas R. Lowy, MD, has been the NCI’s Acting Director since April 2015.
“It is an honor to welcome Dr. Sharpless to the Department of Health and Human Services and the National Institutes of Health,” said Acting Health and Human Services Secretary Eric D. Hargan. “We are grateful to Dr. Lowy for his service as Acting Director, and we look forward to Dr. Sharpless playing an integral role in this administration’s aggressive efforts to advance cancer research and cures for cancer patients.”
“Dr. Sharpless is an outstanding scientist, clinician, and administrator, and we are very fortunate to have him join the NIH leadership team,” said NIH Director Francis S. Collins MD, PhD. “I look forward to his insight, influence, and partnership at NCI, as cancer research is experiencing an unprecedented era of rapid progress.”
Dr. Sharpless comes to NCI from the University of North Carolina School of Medicine, Chapel Hill, where he served as Director of the Lineberger Comprehensive Cancer Center and as the Wellcome Distinguished Professor in Cancer Research. As a practicing oncologist at the N.C. Cancer Hospital, the clinical arm of Lineberger, he specialized in the care of patients with hematologic cancers. He is the author of more than 150 original scientific papers, reviews, and book chapters, and is an inventor on 10 patents. His research has focused on the molecular biology of cancer and aging.
“I am honored and humbled to assume this role at NCI, the world’s premier cancer research institution,” Dr. Sharpless said. “This is an exciting moment for cancer research, as new discoveries and technological improvements are accelerating our progress against cancer, an ancient and unrelenting foe.”
After earning his undergraduate and medical degrees from the University of North Carolina at Chapel Hill, Dr. Sharpless completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. He cofounded two clinical-stage biotechnology companies: G1 Therapeutics and HealthSpan Diagnostics.
Dr. Lowy will resume his role as a Deputy Director at NCI, and will continue his work as Chief of the Laboratory of Cellular Oncology in NCI’s Center for Cancer Research.
ASCO Comments
“ASCO is encouraged that NCI will have at its helm an accomplished researcher with experience leading a wide range of clinical and translational research endeavors focused on bringing new insights into cancer prevention and treatment,” said ASCO President Bruce E. Johnson, MD, FASCO. “We remain committed to NCI’s mission and will continue to advocate for continued support of our nation’s critical investment in its life-saving work.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
